Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: a multicenter retrospective study

This study aimed to survey the efficacy of chemotherapy regimens in the real world setting and explore the most promising regimen for patients experiencing early recurrence for gastric cancer. We retrospectively reviewed the clinical course of 207 patients with gastric cancer, who developed early recurrence during or within 6 months after completing S-1 adjuvant therapy at 19 Japanese institutions between 2012 and 2016. The treatment regimens after recurrence were fluoropyrimidines plus platinum-based regimens (FP) in 91 (44%) patients, paclitaxel-based regimens (PTX) in 102 (49%), and irinotecan-based regimens (IRI) in 14 (7%). The overall response and disease control rates were 28.7% and 54.1%. Median progression-free survival (PFS) and overall survival (OS) were 5.1 and 12.9 months, respectively. In the FP, PTX, and IRI regimens, the median PFS and OS were 5.9, 4.1, 4.1 months and 12.8, 12.9, and 11.8 months, respectively. The combination of PTX and ramucirumab showed survival comparable to capecitabine plus platinum. Multivariate analyses for OS showed that recurrence during adjuvant chemotherapy and undifferentiated histological type were independent poor prognostic factors. Although the prognosis of patients with early recurrence even with adjuvant S-1 was poor, PTX plus ramucirumab therapy could be a potential treatment option.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2024-09-19
DOI
https://doi.org/10.1038/s41598-024-72423-x
Citations
2
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.84
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: a multicenter retrospective study

Koshi Kumagai, Rie Makuuchi, Kengo Nagashima, Shinya Otsuka et al.
2 citations
Scientific Reports
Gastric Cancer Management and Outcomes
0.84
article

Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: a multicenter retrospective study

Koshi Kumagai, Rie Makuuchi, Kengo Nagashima, Shinya Otsuka, HARUHIKO CHO, Shigenori Kadowaki, Takanobu Yamada, Naoki Kakihara, Shusuke Haruta, Takashi Nomura, Narikazu Boku, Toshifumi Yamaguchi, Yoshiro Imai, Shusuke Yagi, Tomohiro Matsushima, Masaya Watanabe, Kentaro Kawakami
article en
2 citations

Abstract

This study aimed to survey the efficacy of chemotherapy regimens in the real world setting and explore the most promising regimen for patients experiencing early recurrence for gastric cancer. We retrospectively reviewed the clinical course of 207 patients with gastric cancer, who developed early recurrence during or within 6 months after completing S-1 adjuvant therapy at 19 Japanese institutions between 2012 and 2016. The treatment regimens after recurrence were fluoropyrimidines plus platinum-based regimens (FP) in 91 (44%) patients, paclitaxel-based regimens (PTX) in 102 (49%), and irinotecan-based regimens (IRI) in 14 (7%). The overall response and disease control rates were 28.7% and 54.1%. Median progression-free survival (PFS) and overall survival (OS) were 5.1 and 12.9 months, respectively. In the FP, PTX, and IRI regimens, the median PFS and OS were 5.9, 4.1, 4.1 months and 12.8, 12.9, and 11.8 months, respectively. The combination of PTX and ramucirumab showed survival comparable to capecitabine plus platinum. Multivariate analyses for OS showed that recurrence during adjuvant chemotherapy and undifferentiated histological type were independent poor prognostic factors. Although the prognosis of patients with early recurrence even with adjuvant S-1 was poor, PTX plus ramucirumab therapy could be a potential treatment option.

Scientific ReportsVol. 14(1)
Tokyo University of Science (JP), Kanagawa Prefectural Hospital Organization (JP), Tokyo Metropolitan Komagome Hospital (JP), Shizuoka Cancer Center (JP), Osaka City General Hospital (JP), Keio University Hospital (JP), Saitama Cancer Center (JP), Fukuyama Cardiovascular Hospital (JP), Keiyukai Sapporo Hospital (JP), Yamagata Prefectural Central Hospital (JP), Aichi Cancer Center (JP), Shizuoka General Hospital (JP), The Cancer Institute Hospital (JP), National Hospital Organization (JP), Osaka International Cancer Institute (JP), Japanese Red Cross Society Kyoto Daini Hospital (JP), Osaka University Hospital (JP), Toranomon Hospital (JP), Kanagawa Cancer Center, Osaka University of Pharmaceutical Sciences (JP)
Good health and well-being
Openalex Percentile: Top 24%
Gastric Cancer Management and Outcomes
0.84
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.